The Tumor Lysis Syndrome
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
The tumor lysis syndrome is the most common disease-related emergency in children and adults with hematologic cancers. This review summarizes current strategies for risk assessment, prophylaxis, and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An important consideration with respect to safety in patients that may have a compromised immune system is that engineered bacterial products are likely to engage both innate and adaptive immunity in the event of release of the organism into the body following tumor lysis75, triggering inflammatory responses.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [75]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802639 · Cited by 1,759
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Pui, C.-H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900386 · Cited by 1,215
Self-citationTumour lysis syndrome: new therapeutic strategies and classification
Cairo, M. S., & Bishop, M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05094.x · Cited by 1,076
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
Coiffier, B., Altman, A., Pui, C.-H., Younes, A., & Cairo, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0177 · Cited by 792
Self-citationCairo, M. S., Coiffier, B., Reiter, A., Younes, A., & Panel, O. B. O. T. T. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08143.x · Cited by 570
Goldman, S. C., Holcenberg, J. S., Finklestein, J. Z., Hutchinson, R., Kreissman, S., Johnson, F. L., Tou, C., Harvey, E., Morris, E., & Cairo, M. S. (2001) · Blood · doi:10.1182/blood.v97.10.2998 · Cited by 477
Cairo, M. S., Gerrard, M., Sposto, R., Auperin, A., Pinkerton, C. R., Michon, J., Weston, C., Perkins, S. L., Raphael, M., McCarthy, K., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036665 · Cited by 363
Pui, C.-H., Mahmoud, H. H., Wiley, J. M., Woods, G. M., Leverger, G., Camitta, B., Hastings, C., Blaney, S. M., Relling, M. V., & Reaman, G. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.697 · Cited by 361
Self-citationOral Phosphate Binders in Patients with Kidney Failure
Tonelli, M., Pannu, N., & Manns, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912522 · Cited by 339
Cited by
Items 401–500 of 1,000
Nephro-oncology: a link in evolution
Lacava, V., Coppolino, G., Puntorieri, E., Cernaro, V., Lupica, R., Visconti, L., Buemi, A., Santoro, D., & Buemi, M. (2015) · Renal Failure · doi:10.3109/0886022x.2015.1068514 · Cited by 9
“An intensive hydration, which should be initiated 24–48 h before the beginning of the therapy and maintained during the entire treatment, and allopurinol administration, are standard prophylactic measures.(33) If the urinary flow is 54–5 L, then the use of diuretics could be appropriated.”
BackgroundIskierka‐Jazdzewska, E., & Robak, T. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2020.1696185 · Cited by 9
“These approaches enable prompt identification and correction of abnormalities in laboratory findings [113].”
BackgroundAlan, A. M., & Alan, Ö. (2020) · Turkish Journal of Emergency Medicine · doi:10.4103/2452-2473.290061 · Cited by 9
“Although we performed aggressive treatment and subsequent hemodialysis, the patient died due to STLS.”
BackgroundInfluentialByron, Y., Nott, L. M., & Shackleton, M. J. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000696 · Cited by 9
Management of Acute Myeloid Leukemia in the Intensive Care Setting
Cowan, A. J., Altemeier, W. A., Johnston, C., Gernsheimer, T., & Becker, P. S. (2014) · Journal of Intensive Care Medicine · doi:10.1177/0885066614530959 · Cited by 9
“Typically, concerns regarding volume overload are less of an issue, and diuretics could be considered to improve urine output if this remains persistently low, to target an output of at least 2 mL/kg/h.(91)”
BackgroundInfluentialTumor Lysis Syndrome and Primary Hepatic Malignancy: Case Presentation and Review of the Literature
Zivin, S. P., Youssef, E., & Ray, C. E. (2015) · Seminars in Interventional Radiology · doi:10.1055/s-0034-1396956 · Cited by 9
A rare seizure: Tumor lysis syndrome after radiation therapy of a solid tumor
Stuart, S. M., & Auten, J. D. (2017) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2017.01.023 · Cited by 9
Shukla, D. K., Gupta, D. K., Aggarwal, A. K., & Kumar, D. P. (2017) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_23_16 · Cited by 9
“[1] Modifications to the 2004 Cairo–Bishop criteria, requiring two or more laboratory criteria within 24 h, and removing the definition of a 25% change in biochemical parameters for the definition of laboratory TLS, were proposed in 2011.[2] As the patient had acute kidney injury, it classifies into clinical TLS.”
MethodWang, Y., Lu, J., & Tao, Y. (2018) · Journal of International Medical Research · doi:10.1177/0300060518776426 · Cited by 9
“However, lower thresholds may be considered in the setting of TLS because of potentially high rates of potassium release and accumulation, particularly in patients with oliguria.(2) In patients with TLS, hyperphosphataemia-induced symptomatic hypocalcaemia may also warrant dialysis.”
BackgroundInfluentialFernandes, J., de Amorim, G. C., da Veiga, T. E., Cardoso, J., Arruda, A. C., Arruda, M. S. P., & Castelo-Branco, M. T. L. (2019) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-019-01661-6 · Cited by 9
Spontaneous Tumor Lysis Syndrome in an Adenocarcinoma of Unknown Origin
Kalter, J. A., Allen, J., Yang, Y., Willing, T. F., & Evans, E. (2020) · Cureus · doi:10.7759/cureus.12169 · Cited by 9
“Several factors increase the risk of TLS development, such as high tumor burden, preceding renal injury, malignant liver and spleen infiltration, high proliferative rate, and sensitivity to chemotherapy [1].”
BackgroundInfluentialGelen, S. A., Sarper, N., Zengin, E., & Azizoğlu, M. (2021) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002225 · Cited by 9
Rasool, M., Malik, A., Qureshi, M. S., Ahmad, R., Manan, A., Asif, M., Naseer, M. I., & Pushparaj, P. N. (2014) · Bioinformation · doi:10.6026/97320630010703 · Cited by 9
Rasburicase for Huge Hepatocellular Carcinoma with Tumor Lysis Syndrome: Case Report
Chao, C., & Chiang, C. (2012) · Medical Principles and Practice · doi:10.1159/000339083 · Cited by 9
Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib
Farooqi, B., Simmons, J. D., & Hao, Z. (2015) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-015-9711-6 · Cited by 9
“Tumor lysis syndrome (TLS) is an oncologic emergency that occurs more often in hematological malignancies, such as non-Hodgkin’s lymphomas or acute leukemias [1].”
BackgroundChanging the terminology from kidney replacement therapy to kidney support therapy
Raina, R., Joshi, H., & Chakraborty, R. (2020) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13584 · Cited by 8
“According to several sources, severe VOD has mortality rates greater than 80%.(27,28) Progressive FO and electrolyte imbalance can occur despite medical management and lead to progressive oliguria and MOD (indicator of severe VOD), requiring support in the form of KRT.”
BackgroundReview of Hematology-Oncology Emergencies for Internal Medicine Residents
Baralo, B., Ramesh, N., Deshpande, S., Buragamadagu, B. C., Khanam, A., Paravathaneni, M., Mulla, S., Bedi, V., Thota, V., Baralo, R., et al. (2023) · Cureus · doi:10.7759/cureus.33563 · Cited by 8
“If present, symptomatic hypocalcemia (tetany, carpopedal spasm, seizures, or prolonged QTc)should be treated using intravenous calcium gluconate [10,11].”
BackgroundBíró, E., Erdelyi, D. J., Varga, P., Sinkó, M., Bartyik, K., Kovács, G., Ottóffy, G., Vincze, F., Szegedi, I., Kiss, C., et al. (2023) · Pediatric Nephrology · doi:10.1007/s00467-023-05923-z · Cited by 8
“This retrospective clinical investigation was carried out between 2006 and 2016 and included children with leukemia and non-Hodgkin lymphoma (NHL) with at least two laboratory abnormalities characteristic of TLS according to the Cairo–Bishop criteria [2, 15].”
MethodDukmak, O. N., Ayyad, M., Albandak, M. E., Hamadah, A. M., & Gharaibeh, K. A. (2023) · Cureus · doi:10.7759/cureus.38815 · Cited by 8
“These electrolyte abnormalities account for the major morbidity and mortality associated with this condition, leading to various, possibly fatal clinical manifestations, including acute kidney injury (AKI), seizures, arrhythmias, and multi-organ system failure [2].”
BackgroundYang, X., Li, H., Qumu, D., Han, B., Amatjan, M., Wu, Q., Wei, L., Li, B., Ma, M., He, J., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1587198 · Cited by 8
“UA can cause precipitation and obstruction in the renal tubules, which can lead to acute kidney injury, especially in the case of tumor lysis syndrome (4).”
Martínez-Jiménez, D., Garner, B. C., Coutermarsh‐Ott, S. L., Burrell, C. E., Clark, S. D., Nabity, M. B., Díaz‐Delgado, J., Hoffmann, A. R., Zaks, K. L., Proença, L. M., et al. (2017) · Journal of Veterinary Diagnostic Investigation · doi:10.1177/1040638716687603 · Cited by 8
“Single cell necrosis and degranulation were common features, the latter of which was often associated with intravascular aggregates of karyorrhectic cellular debris, vascular endothelial necrosis, thrombosis, and hemorrhages, resembling typical features of acute tumor lysis syndrome.(9) The marrow cytoarchitecture was…”
BackgroundChemotherapy in the Intensive Care Unit: An Evaluation of Context and Outcomes
Kanji, S., MacLean, E., Rashid, F. J., Pittman, M., Trinacty, M., Allan, D., Rosenberg, E., & Resource Optimization Network (2020) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v73i4.3027 · Cited by 8
Ghosh, S., Tilak, T., Somasundaram, V., & Mutreja, D. (2021) · SciMedicine Journal · doi:10.28991/scimedj-2021-0301-6 · Cited by 8
“The bulky masses and bone marrow involvement are risk factors for tumor lysis syndrome [8].”
BackgroundGoto, H., Ito, S., Kizaki, M., Yamaguchi, M., Fukuhara, N., Kato, K., Saito, T., Terui, Y., Okubo, S., Soshin, T., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02443-6 · Cited by 8
“Of note, three cases of hyperkalemia were observed, but none one them were associated with TLS per investigators, nor did they meet Howard’s criteria [15].”
BackgroundMethodMartínez‐Sáez, O., Mezquita, L., Caravaca‐Fontán, F., Reguera, P., Molina, J. R., Olmedo, M. E., & Garrido, P. (2016) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2016.08.005 · Cited by 8
Findakly, D., & Wang, J. (2020) · Cureus · doi:10.7759/cureus.7395 · Cited by 8
Carrier, X., Gaur, S., & Philipovskiy, A. V. (2020) · American Journal of Case Reports · doi:10.12659/ajcr.925248 · Cited by 8
“[27] describes key features associated with a higher possibility of TLS.”
BackgroundStilgenbauer, S., Morschhauser, F., Wendtner, C., Cartron, G., Hallek, M. J., Eichhorst, B. F., Kozloff, M. F., Giever, T. A., Lozanski, G., Jiang, Y., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.261107 · Cited by 8
Greguska, C. (2020) · JAAPA · doi:10.1097/01.jaa.0000723908.23506.85 · Cited by 8
Ranjan, A., Kishore, D., Ashar, H. K., Neel, T., Singh, A., & More, S. (2021) · International Journal of Hyperthermia · doi:10.1080/02656736.2021.1903582 · Cited by 8
“These metabolic disturbances can cause cardiac toxicity and neurophysiological abnormalities [45,46].”
BackgroundAndo, H., Murakami, Y., Eshima, K., & Ishida, T. (2021) · Cancer Reports · doi:10.1002/cnr2.1485 · Cited by 8
“7%) of patients with clinical and laboratory TLS tend to experience one or more of the following adverse side effects: an increase in creatinine, cardiac arrhythmia or sudden death, and/or seizure.(18,19) In clinical trials, treatment with VTX has caused grade 3/4 adverse events that include neutropenia (39.”
BackgroundInfluentialWang, Y., Wang, T., Xue, J., Jia, Z., Liu, X., Li, B., Li, J., Li, X., Wang, W., Bing, Z., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.809467 · Cited by 8
“It is induced by a massive release of intracellular contents into the circulation when tumour cells breakdown spontaneously or after the initiation of chemotherapy (Howard et al., 2011).”
BackgroundKilani, Y., Laxamana, T., Mahfooz, K., Yusuf, M. H., Perez-Gutierrez, V. A., & Shabarek, N. (2022) · American Journal of Case Reports · doi:10.12659/ajcr.935915 · Cited by 8
Chen, K., Dai, M., Luo, Q., Wang, Y., Shen, W., Liao, Y., Zhou, Y., & Cheng, W. (2022) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2022.106358 · Cited by 8
Rare Adverse Events of CAR T-Cell Therapy
Müller, A. M. S. (2024) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2024.19.138 · Cited by 8
Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma
Lee, J. Y., Lim, S. H., Lee, J. Y., Kim, J. H., Choi, K. H., Park, K., Sun, J., Ahn, J. S., & Ahn, M. (2013) · Cancer Research and Treatment · doi:10.4143/crt.2013.45.4.343 · Cited by 8
Spontaneous tumor lysis syndrome in a patient with newly diagnosed metastatic colonic adenocarcinoma
Berringer, R. (2017) · Canadian Journal of Emergency Medicine · doi:10.1017/cem.2017.378 · Cited by 8
Hematological malignancies presenting as spontaneous tumor lysis syndrome: A case series
Kollathodi, S. B., Parameswaran, K. K., Madhavan, L., & Kuruvilla, S. (2018) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_171_18 · Cited by 8
“Modification to this criteria was proposed in 2011.[6] When patients with laboratory TLS develop complications like seizure, renal failure, arrhythmia, or sudden death, it is called clinical TLS.”
BackgroundMoia, R., Boggio, E. M., Gigliotti, C. L., Crisà, E., Paoli, L. D., Casaluci, G. M., Rolla, R., Patriarca, A., Gaïdano, G., Dianzani, U., et al. (2020) · Hematological Oncology · doi:10.1002/hon.2700 · Cited by 8
“To the Editor, Rasburicase is a recombinant urate oxidase enzyme that rapidly metabolizes uric acid into allantoin, a more soluble and rapidly secreted metabolite.(1-3) Since the rasburicase protein is derived from genetically modified Saccharomyces cerevisiae, it may have immunogenic properties and may elicit antibod…”
BackgroundITM2B Truncation Promotes Migrasome Formation to Accelerate Renal Cell Carcinoma Growth
Chen, Q.-T., Huang, Q., Han, M., Hong, X., Feng, D., Yao, L., Hong, W., Chen, Y., Huang, Y., Chen, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202511683 · Cited by 7
Trevisani, F., Simeoni, M., Bettiga, A., Cinque, A., & Floris, M. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000538854 · Cited by 7
Han, Y., Yue, P., & Yuan, Z. (2025) · International Journal of Emergency Medicine · doi:10.1186/s12245-025-00879-3 · Cited by 7
“Theo-retically, after such interventions, aggressive intravenous hydration can improve outcomes for high-risk patients by enhancing renal perfusion, glomerular filtration, and urine output [28].”
Acute Postoperative Pain Management
Quiñónez, Z. A., & Sinton, J. W. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108668736.056 · Cited by 7
Tarčuković, J., Valenčić, L., Polonijo, Ž., Fućak, A., Dangubić, B., & Grubješić, I. (2019) · Case Reports in Critical Care · doi:10.1155/2019/2358562 · Cited by 7
“TLS is potentially lethal oncologic emergency [1, 3, 8, 11].”
Goodrich, A. (2021) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2021.12.1.5 · Cited by 7
“…systems for clinical and/or laboratory TLS include the National Cancer Institute’s Common Terminology Criteria for Adverse Events, the Cairo-Bishop classification system, and the modified Cairo-Bishop system (Cairo & Bishop, 2004; Howard et al., 2011; National Cancer Institute, 2017).”
InfluentialBrown, R. B. (2022) · Metabolites · doi:10.3390/metabo12121284 · Cited by 7
““These electrolyte and metabolic disturbances can progress to clinical toxic effects, including renal insufficiency, cardia arrhythmias, eizures, nd death due to multiorga failure” [22].”
BackgroundRasburicase in treating tumor lysis syndrome: An umbrella review
Mahfooz, K., Sohail, H., Gvajaia, A., Arif, U., Grewal, D., Muppidi, M. R., Vohra, V., Tarique, A., & Vasavada, A. M. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.07.001 · Cited by 7
A Case of Tumor Lysis Syndrome during Palliative Radiotherapy for Breast Cancer Metastases
FURUSAWA, M., Matsuishi, K., Horino, K., Inoue, H., Abe, M., & Oya, N. (2023) · Case Reports in Oncology · doi:10.1159/000531925 · Cited by 7
Li, D., Qin, C., Wang, H., Du, D., Wang, Y., Du, Q., & Liu, S. (2024) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241274909 · Cited by 7
“2,4,5 It is reported that the incidence of TLS ranges from 3% to 40% among patients with high-risk hematological malignancies, 6 and the overall in-hospital mortality of TLS can even reach 28% in patients with certain types of cancer.”
BackgroundKwiatek, M., Murthy, G. S. G., Hoffmann, M., Tessoulin, B., Danilov, A. V., Alencar, A. J., Shah, N. N., Ghesquières, H., Gouill, S. L., Jurczak, W. J., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.01.018 · Cited by 7
Middeke, J. M., Brück, N., Parmentier, S. B., Bornhäuser, M., & Schetelig, J. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1836-8 · Cited by 7
“The efficacy and safety has been demonstrated in several studies [2].”
BackgroundHypercalcemia in Tumor Lysis Syndrome
Shah, B. K. (2013) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-013-0264-1 · Cited by 7
“It is associated most often with Non Hodgkin’s lymphoma and acute leukemias, although it is not uncommon in other malignancies [1].”
BackgroundTumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer
Boikos, S. A., Forde, P. M., Chatterjee, S., & Hann, C. L. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318286bb3b · Cited by 7
Li, W. H. C., Chung, J. O. K., Tam, C. J., & Chiu, S. Y. (2015) · Journal of Pediatric Oncology Nursing · doi:10.1177/1043454214555551 · Cited by 7
“As calcium phosphate is more soluble at an acidic pH, urinary alkalinization may hinder the excretion of phosphorus, which can lead to increased calcium-phosphate crystallization and precipitation in the renal tubules (Coiffier et al., 2008; Howard et al., 2011; Tazi et al., 2011).”
BackgroundLeukemoid Reaction in a Pediatric Patient With Diabetic Ketoacidosis
Gonzalez, L. K., Malhotra, S., Levine, M. C., & Jacobson-Dickman, E. E. (2015) · Pediatric Emergency Care · doi:10.1097/pec.0000000000000558 · Cited by 7
“Our patient's initial presentation to the emergency department with DKAwith severe leukocytosis and concomitant hyperkalemia, hyperphosphatemia, hyperuricemia, elevated LDH, and renal insufficiency prompted concern for leukemia with tumor lysis syndrome.(2) This presented a management challenge as treatment for this e…”
BackgroundFriedman, M., Patel, P. R., & Rondelli, D. (2015) · Seminars in Interventional Radiology · doi:10.1055/s-0035-1549846 · Cited by 7
Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report
van Kalleveen, M. W., Walraven, M., & Hendriks, M. P. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0576-y · Cited by 7
“proposed a refinement of the Cairo and Bisshop classification of TLS [7].”
BackgroundMethodA Rare Case of Spontaneous Tumor Lysis Syndrome in Idiopathic Primary Myelofibrosis
Na, Y. S., & Park, S.-G. (2019) · American Journal of Case Reports · doi:10.12659/ajcr.912682 · Cited by 7
“They defined clinical TLS as laboratory TLS occurring with 1 or more of these complications: renal failure, cardiac arrhythmia, seizure, and sudden death [6,7].”
BackgroundTumor Lysis Syndrome in Chronic Lymphocytic Leukemia: A Rare Case Report from Nephrology
Armaly, Z., Elias, M. S., Yasin, R., Hamzeh, M., Jabbour, A. R., Artoul, S., & Saffouri, A. (2019) · American Journal of Case Reports · doi:10.12659/ajcr.917211 · Cited by 7
“The Cairo-Bishop criteria requires 2 or more defined laboratory abnormalities with a 25% change from baseline occurring at any time within 3 days prior or 7 days after chemotherapy [20], and the Howard criteria which is a modification of the Cairo-Bishop criteria, omits the need for a 25% change in laboratory values a…”
BackgroundMethodInfluentialA Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome
Öztürk, E., & Özünal, I. E. (2021) · Medeniyet Medical Journal · doi:10.5222/mmj.2021.56424 · Cited by 7
Hajjar, A. H., Abbarh, S., Al-Mashdali, A. F., Alshurafa, A., Abu‐Tineh, M., Qasim, H., Ahmed, K., & Yassin, M. A. (2022) · Cureus · doi:10.7759/cureus.24386 · Cited by 7
“Usually, these abnormalities occur rapidly, exceeding the body homeostasis, and may result in acute kidney injury (AKI), severe arrhythmias, multiorgan failure, or even death [3].”
BackgroundKaland, D. A., Dores, G. M., Nayernama, A., & Camilli, S. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.08.014 · Cited by 7
Disorders of Calcium and Magnesium
Wynne, Z., & Falat, C. (2023) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2023.07.004 · Cited by 7
Myint, Z. W., Verla‐Tebit, E., Cho, B. B., Goodner, S. A., Stelow, E. B., Weiss, G. R., & Fracasso, P. M. (2015) · Cancer Treatment Communications · doi:10.1016/j.ctrc.2015.03.002 · Cited by 7
Rozentryt, P., Nowak, J. U., Niedziela, J. T., Hudzik, B., Doehner, W., Jankowska, E. A., von Haehling, S., Partyka, R., Kawecka, E., Myrda, K., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.034 · Cited by 7
“Firstly, tissue hypoxia found inmore advanced stages of HF may induce phosphorus translocation from cells similar to that in tumor lysis syndrome [5].”
BackgroundJiang, R.-D., Jian, W., Jin, N., Zhang, Z., & Li, T. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.04.019 · Cited by 7
Steroid-induced tumour lysis syndrome in small-cell lung cancer
Khan, F., Ayub, S., Mehmood, Q., & Hussain, S. F. (2017) · Oxford Medical Case Reports · doi:10.1093/omcr/omx018 · Cited by 7
“These exhaust the body’s homeostatic mechanisms resulting in the characteristic findings of hyperuricaemia, hyperkalaemia, hyperphosphataemia and hypocalcaemia [6].”
BackgroundLiu, Y., Zhao, C., Gao, L., Yang, H., He, R., & Gao, C. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.216 · Cited by 7
“11 Clinical outcomes of CAR T-cell therapy were better when patients received lympho-depleting chemotherapy that could enhance the activity of CAR T cells and increase levels of several homeostatic cytokines and chemokines.”
Bruton’s tyrosine kinase inhibitors and the kidney: Focus on ibrutinib
Brener, Z. Z., Brener, H., & Losev, A. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220904406 · Cited by 7
“Tumor lysis syndrome (TLS) is an oncologic emergency resulting from rapid and massive tumor cell death that may lead to serious clinical complications, including acute kidney injury (AKI) and cardiac arrest.(1) TLS most often occurs after the initiation of cytotoxic therapy in patients with high-grade lymphomas and ac…”
Background[Metabolic emergencies in critically ill cancer patients].
Ñamendys-Silva, S. A., Hernández-Garay, M., García-Guillén, F. J., Correa-García, P., Herrera‐Gómez, Á., & Meneses-García, A. (2013) · PubMed · doi:10.3305/nutrhosp.v28in06.6959 · Cited by 7
Godo, S., Yoshida, Y., Kawamorita, N., Mitsuzuka, K., Kawazoe, Y., Fujita, M., Kudo, D., Nomura, R., Shimokawa, H., & Kushimoto, S. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0262-17 · Cited by 7
“An alternate explanation for the sudden onset of hyperkalemia in this patient may be tumor lysis syndrome, which is characterized by acute and severe hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia in response to anticancer therapy, leading to cardiac arrhythmia, acute kidney injury, and seizure (16).”
BackgroundComputational Approach for Rational Design of Fusion Uricase with PAS Sequences.
Najjari, A., Rahimi, H., Nojoumi, S. A., & Omidinia, E. (2020) · PubMed Central · doi:10.22088/ijmcm.bums.9.1.90 · Cited by 7
“com umor lysis syndrome (TLS) indicates the metabolic events caused by massive tumor cell lysis leading to the release of intracellular contents into the bloodstream (1-3).”
BackgroundUse of rasburicase to improve kidney function in children with hyperuricemia and acute kidney injury
Herrero-Goñi, M., Irazábal, A. Z., Madariaga, L., Chavarri-Gil, E., Gondra, L., & Aguirre, M. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02394-2 · Cited by 6
Tumor lysis syndrome following letrozole for locally advanced breast cancer: a case report
Kikuchi, M., Miyabe, R., Matsushima, H., Kita, H., Kobayashi, J., Ando, T., Atsuta, K., & Shintani, T. (2024) · Surgical Case Reports · doi:10.1186/s40792-024-01901-1 · Cited by 6
“TLS has also been commonly reported in hematological malignancies but is becoming more frequently noted in solid tumors as treatments become more efficient [11].”
BackgroundChow, M., Yuwono, A., & Tan, R. B. W. (2015) · Asian journal of urology · doi:10.1016/j.ajur.2015.09.005 · Cited by 6
“This helps improve renal perfusion and glomerular filtration and minimizes acidosis (which promotes the precipitation of uric acid crystals) [1].”
BackgroundInfluentialGilbert, S. J., & Wright, S. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2659-6_8 · Cited by 6
Recognizing and preventing tumor lysis syndrome
Kaplow, R., & Iyere, K. (2016) · Nursing · doi:10.1097/01.nurse.0000502751.87828.2d · Cited by 6
Spontaneous tumor lysis syndrome in squamous cell carcinoma of the lung
Din, M. A. U., Hussain, S. A., Boppana, L. K. T., Manogna, D., & Imran, F. S. (2020) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2020.1818911 · Cited by 6
“Laboratory TLS requires at least two or more of the following derangements without any clinical symptoms: hyperuricemia, hyperkalemia, hypocalcemia, hyperphosphatemia, high creatinine, and low urine output.(3) Clinical TLS requires the presence of laboratory TLS in association with acute kidney injury, symptomatic hyp…”
BackgroundInfluentialYulistiani, Y., Tiffany, C., Ugrasena, I. D. G., & Qibtiyah, M. (2021) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2020-0412 · Cited by 6
Chou, J., Cheng, K.-S., Akella, T., Lee, C. C., & Ju, T. R. (2021) · Cureus · doi:10.7759/cureus.19128 · Cited by 6
“Second, AKI and electrolyte imbalance resulting from other etiologies was a common finding in patients with cirrhosis or HCC [33].”
BackgroundInfluentialZhang, Q., Zu, C., Meng, Y., Lyu, Y., Hu, Y., & Huang, H. (2022) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2022-0038 · Cited by 6
Bozkurt, S., Genç, D. B., & Vural, S. (2024) · BMC Pediatrics · doi:10.1186/s12887-024-04549-w · Cited by 6
“The incidence of TLS varies depending on many reasons including the presence of tumors with a high proliferation rate, heterogeneity of the patient population and treatment regimens, differences in TLS prophylaxis, and the lack of a universal TLS definition [9, 31].”
BackgroundVDX‐111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression
Persenaire, C., Babbs, B. L., Yamamoto, T. M., Nebbia, M., Jordan, K. R., Adams, S. F., Lambert, J. R., & Bitler, B. G. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23721 · Cited by 6
“30 During tumor lysis, dying tumor cells release protein, nucleic acids, and metabolites into the tumor microenvironment and vasculature, causing both inflammation and resultant side effects.”
BackgroundTumor Lysis Syndrome Following PSMA Radioligand Therapy
Sahafi, P., Saeed, M., Samadi, M. H., Aryana, K., & Askari, E. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005445 · Cited by 6
Salomon, O., Holtzman, E. J., Beckerman, P., Avivi, C., Trakhtenbrot, L., Kneller, A., Tohami, T., Kleinbaum, Y., Apter, S., Amariglio, N., et al. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-24 · Cited by 6
“TLS can occur spontaneously [10], but it is commonly seen following the initiation of anticancer treatment [9].”
BackgroundInfluentialMathers, B., Harvey, H. A., Dye, C. E., Dougherty-Hamod, B., & Moyer, M. T. (2014) · Endoscopy International Open · doi:10.1055/s-0034-1377612 · Cited by 6
High Intensity Focused Ultrasound Treatment-Induced Tumor Lysis Syndrome in Uterine Myoma Patient
Park, J.-H., Yang, I.-M., Kim, Y.-H., Yu, S. J., Lee, J. S., & Kim, D. H. (2015) · Soonchunhyang Medical Science · doi:10.15746/sms.15.022 · Cited by 6
“However, TLS is uncommon in solid tumor [2,5].”
BackgroundSpontaneous tumour lysis syndrome associated with contrast dye iohexol use in mantle cell lymphoma
Yun, S., Vincelette, N. D., Phan, T., & Anwer, F. (2014) · BMJ Case Reports · doi:10.1136/bcr-2014-204113 · Cited by 6
Citrin, R., Getz, K., Li, Y., Huang, Y.-S. V., Horowitz, J. P., Seif, A. E., Fisher, B. T., & Aplenc, R. (2018) · British Journal of Haematology · doi:10.1111/bjh.15159 · Cited by 6
Khalighi, P. R., Martens, K. L., White, A. A., Li, S., Silgard, E. T., Frieze, D. A., Garcia, D. A., & Li, A. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219851543 · Cited by 6
“Tumor lysis syndrome (TLS) is characterized by the sudden systemic release of intracellular contents, which may occur as a result of cytotoxic therapy.(1) The metabolic derangements of TLS, including hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, may cause serious consequences, including seizures, c…”
BackgroundOvarian stimulation and egg retrieval in the acutely ill patient: special considerations
Wald, K., Letourneau, J. M., McKay, R. E., Monks, J., Mok-Lin, E. Y., Cedars, M. I., & Rosen, M. P. (2019) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-019-01556-0 · Cited by 6
Tumor Lysis Syndrome After Laparoscopic Microwave Ablation of Colorectal Liver Metastases
Sheka, A. C., Altman, A. M., GASPARETTO, A., Spilseth, B., Muratore, S. L., & Jensen, E. H. (2019) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-019-00308-8 · Cited by 6
Hu, Y., Jin, J., Zhang, Y., Hu, J., Li, J., Wei, X., Gao, S., Zha, J., Jiang, Q., Wu, J., et al. (2021) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2021.04.004 · Cited by 6
Ganapathi, M., Campbell, P., Ofori, K., Aggarwal, V. S., Francis, R. O., & Kratz, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15353 · Cited by 6
“Tumour lysis syndrome is a highly prevalent adverse outcome associated with treating several malignancies, especially haematologic malignancies, with an incidence exceeding 10%.(6) Due to the urgent need for rasburicase administration when clinical or laboratory tumour lysis is diagnosed, prior knowledge of G6PD statu…”
BackgroundMenakuru, S. R., Priscu, A., Khan, I., & Beirat, A. F. (2022) · Case Reports in Oncology · doi:10.1159/000524198 · Cited by 6
Zhang, X., Tu, Y., Shen, J., Feng, Y., Ma, H., Bai, L., Li, X., Lin, Z., Dai, L., Gong, F., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2086246 · Cited by 6
“Prophylactic calcium supplementation should be provided for such patients before leukapheresis [39] to prevent severe hypocalcemia symptoms such as muscle cramps and tetany.”
BackgroundAcute Tubular Injury and Acute Tubular Necrosis
Turner, J. M., & Coca, S. G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-47794-9.00032-9 · Cited by 6
Tsai, W.-L., Liang, P., & Chen, C. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2011.12.009 · Cited by 6
“When tumor lysis syndrome develops, treatment with aggressive hydration, allopurinol, rasburicase, and urine alkalinization is warranted.(1,2) Aggressive hydration can rapidly improve renal perfusion and glomerular filtration and minimize acidosis.”
BackgroundAcute tumor lysis syndrome after anti-pd-1 immunotherapy nivolumab for metastatic melanoma.
Brunnhoelzl, D., & Wang, J. (2017) · doi:10.35841/molecular-oncology.1.1.5-6 · Cited by 6
“Tumor lysis syndrome (TLS) is an oncological emergency caused by the sudden, rapid death of cancer cells spontaneously or after chemotherapy, commonly in patients with aggressive lymphomas and leukemias, [1-3].”
BackgroundWang, H., Chen, G., Gao, H., & Yi, Z. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-1158 · Cited by 6
“It is characterized by the development of acute kidney injury and other metabolic abnormalities including hyperuricemia, hyperkalemia, hypocalcemia and hyperphosphatemia after effective treatment (4).”
Background
Metadata
- Authors
- Howard, S. C., Jones, D. P., & Pui, C.-H.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-12
- Volume
- 364
- Issue
- 19
- Pages
- 1844-1854
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3437249
- OpenAlex
- W2122479144
- Cited by
- 1,044
- References
- 58
- Citations by year
- 2026: 71 · 2025: 67 · 2024: 86 · 2023: 71 · 2022: 69 · 2021: 81 · 2020: 89 · 2019: 154 · 2018: 60 · 2017: 53 · 2016: 49 · 2015: 57 · 2014: 47 · 2013: 49 · 2012: 31
- FWCI
- 36.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA21765, P30CA021765)
- National Institute of General Medical Sciences (U01GM92666, U01GM092666)
- Topics
- Health Sciences › Medicine › Hematology › Methemoglobinemia and Tumor Lysis Syndrome
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
- Keywords
- tumor lysis syndrome, hematologic malignancies, risk assessment, prophylaxis, treatment, pediatric oncology, emergency management
- MeSH terms
- Child, Humans, Male, Tumor Lysis Syndrome, Risk Assessment, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.